Addex Therapeutics Ltd.
ADXN evidence brief
What we can confirm
- Market Cap:
- $4.4M
What it means
What to watch
Prepared research question
What matters most for ADXN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADXN
Addex Therapeutics Ltd. (ADXN) is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, with a focus on its GABAB PAM portfolio and ongoing clinical programs.
Key risk: Accumulated deficit
Market Cap
$4.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Addex Therapeutics Ltd. (ADXN) is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, with a focus on its GABAB PAM portfolio and ongoing clinical programs.
- Addex is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [news · published 2026-09-24].
- The company raised USD 2.8 million through its ATM agreement in August 2026, extending cash runway into Q4 2027 [news · published 2026-08-26].
- Addex regained full global rights to its GABAB positive allosteric modulator (PAM) portfolio from Indivior in September 2026 [news · published 2026-09-25].
- The company reported its 2026 Half-Year and Second Quarter financial results on September 28, 2026 [news · published 2026-09-28].
- Preclinical data published in Molecular Psychiatry in February 2026 support the potential of mGlu7 negative allosteric modulators for anxiety and fear-related disorders [news · published 2026-02-03].
What works
- Addex successfully raised USD 2.8 million in August 2026, extending its cash runway into the fourth quarter of 2027, providing financial stability for ongoing operations [news · published 2026-08-26].
- The company regained full global rights to its GABAB PAM portfolio from Indivior in September 2026, consolidating control over a key asset class [news · published 2026-09-25].
- Preclinical data published in Molecular Psychiatry in February 2026 demonstrated the potential of mGlu7 negative allosteric modulators to transform treatment of anxiety and fear-related disorders, indicating a promising pipeline candidate [news · published 2026-02-03].
What to weigh
- Addex reported a net loss of USD 4.4 million for the first half of 2026, with accumulated deficit reaching USD 156.9 million as of June 30, 2026 [news · published 2026-09-28].
- The company experienced executive management changes in October 2026, including the departure of Head of Translational Science Mikhail Kalinichev, which may impact pipeline momentum [news · published 2026-10-02].
- Addex's clinical programs, including dipraglurant for dyskinesia and blepharospasm, remain in early stages (Phase 2/3) with no approved products, exposing the company to clinical and regulatory risks [catalyst].
Catalyst timeline
- 2021-08-06 · Phase 2b/3 study start for dipraglurant in Parkinson's disease dyskinesia — Randomized, double-blind, placebo-controlled study evaluating safety and efficacy of dipraglurant for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy.
- 2021-10-06 · Phase 2a study start for dipraglurant in blepharospasm — Exploratory Phase 2a randomized, double-blind, placebo-controlled study of dipraglurant immediate release tablets in patients with blepharospasm.
- 2021-10-25 · Open-label safety study start for dipraglurant in Parkinson's disease — Open-label safety study of dipraglurant in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopaminergic medications.
- 2026-09-28 · Earnings report for 2026 half-year results — Addex Therapeutics reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.
Risks & what to watch (4)›
Key risks
- Accumulated deficit — Accumulated deficit of USD 156.9 million as of June 30, 2026, reflecting sustained losses [news · published 2026-09-28].
- Clinical stage risk — All programs are in clinical or preclinical stages; no approved products, with dipraglurant in Phase 2/3 for dyskinesia [catalyst].
- Management turnover — Head of Translational Science stepped down in October 2026, potentially disrupting pipeline execution [news · published 2026-10-02].
- Cash runway dependency — Cash runway extended to Q4 2027 via ATM raise, but future financing needs remain uncertain [news · published 2026-08-26].
What to watch
- Progress of dipraglurant Phase 2b/3 study for dyskinesia in Parkinson's disease, with start date of 2021-08-06 [catalyst].
- Development of GABAB PAM portfolio following regained rights from Indivior in September 2026 [news · published 2026-09-25].
- Advancement of mGlu7 negative allosteric modulator program for anxiety and fear-related disorders, supported by preclinical data published February 2026 [news · published 2026-02-03].
- Financial sustainability and potential need for further capital raises beyond the current cash runway into Q4 2027 [news · published 2026-08-26].
Sources: Catalysts · News · Generated October 3, 2026 · How we verify sources →
Run Addex Therapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Addex Therapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$3K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 301 | $2K |
| gamma investing llc | 81 | $509 |
| rhumbline advisers | 72 | $450 |
| sbi securities co., ltd. | 1 | $6 |
Short Interest
as of May 1, 2026- % of float
- 0.7%
- Days to cover
- 1.3
- Shares short
- 7,260
- Daily short volume (Oct 12, 2026)
- 17.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADXN short interestFrequently asked questions
What is the AI investment thesis for Addex Therapeutics Ltd.?
Addex Therapeutics Ltd. (ADXN) is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, with a focus on its GABAB PAM portfolio and ongoing clinical programs.
Who is the CEO of Addex Therapeutics Ltd.?
Mr. Timothy Mark Dyer is the chief executive officer of Addex Therapeutics Ltd. (ADXN).
Where is Addex Therapeutics Ltd. headquartered?
Addex Therapeutics Ltd. (ADXN) is headquartered in Geneva, Switzerland.
What therapeutic areas does Addex Therapeutics Ltd. focus on?
Addex Therapeutics Ltd. develops therapies across Neurology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.